Clinical Trial Details
| Trial ID: | L1758 |
| Source ID: | NCT00463021 |
| Associated Drug: | Hectorol (Doxercalciferol Capsules) |
| Title: | A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Secondary Hyperparathyroidism |
| Interventions: | DRUG: Hectorol (doxercalciferol capsules)|DRUG: Zemplar (paricalcitol injection) |
| Outcome Measures: | Primary: Dose Conversion, 10 weeks | |
| Sponsor/Collaborators: | Sponsor: Genzyme, a Sanofi Company |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 36 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2007-04 |
| Completion Date: | 2007-12 |
| Results First Posted: | |
| Last Update Posted: | 2015-05-05 |
| Locations: | Downey, California, United States|Paramount, California, United States|Hudson, Florida, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States |
| URL: | https://clinicaltrials.gov/show/NCT00463021 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|